Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Income (2016 - 2026)

Ironwood Pharmaceuticals' Non Operating Income history spans 16 years, with the latest figure at -$6.4 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 15.29% to -$6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$28.5 million, a 1.97% decrease, with the full-year FY2025 number at $193000.0, down 97.62% from a year prior.
  • Non Operating Income hit -$6.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$7.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for IRWD hit a ceiling of $6.9 million in Q2 2023 and a floor of -$10.7 million in Q2 2021.
  • Historically, Non Operating Income has averaged -$4.4 million across 5 years, with a median of -$6.2 million in 2024.
  • The widest YoY moves for Non Operating Income: up 517.38% in 2023, down 664.23% in 2023.
  • Tracing IRWD's Non Operating Income over 5 years: stood at -$10.3 million in 2021, then surged by 137.75% to $3.9 million in 2022, then crashed by 285.26% to -$7.2 million in 2023, then dropped by 3.69% to -$7.5 million in 2024, then rose by 15.29% to -$6.4 million in 2025.
  • Business Quant data shows Non Operating Income for IRWD at -$6.4 million in Q4 2025, -$7.5 million in Q3 2025, and -$7.5 million in Q2 2025.